Immutep Reports Positive Phase I Data for First-in-Class Autoimmune Antibody IMP761

Immutep ( (IMMP) ) has issued an announcement.

On 22 December 2025, Immutep reported positive initial results from a placebo-controlled, double-blind first-in-human Phase I trial of IMP761, its first-in-class LAG-3 agonist antibody for autoimmune diseases, in healthy volunteers. The single-ascending dose part of the study has now successfully completed the 2.5 mg/kg and 7 mg/kg cohorts, with IMP761 showing a favourable safety profile limited to mild treatment-related effects and demonstrating dose-dependent, long-lasting immunosuppressive activity, including substantial inhibition of T cell-driven intradermal reactions to a strong foreign antigen through day 23. These proof-of-concept data support the drug’s potential to silence dysregulated memory T cells driving autoimmune disease and underline the strategic importance of the program in a multi‑billion‑dollar market segment, with the company indicating that the trial will continue as planned and that additional data are expected in the first half of 2026, reinforcing Immutep’s positioning as a frontrunner in LAG-3–based therapeutics for autoimmunity.

The most recent analyst rating on (IMMP) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.

Spark’s Take on IMMP Stock

According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.

Immutep’s overall stock score is primarily impacted by its challenging financial performance, characterized by persistent losses and negative cash flows. However, positive technical indicators provide some optimism, suggesting potential short-term momentum. The valuation remains weak due to negative earnings, typical for a biotech firm in its development phase.

To see Spark’s full report on IMMP stock, click here.

More about Immutep

Immutep Limited is a late-stage biotechnology company specialising in novel immunotherapies for cancer and autoimmune diseases, with a particular focus on drugs targeting the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. The company’s diversified pipeline aims either to stimulate or suppress the immune system, positioning Immutep to address large, high-value markets such as rheumatoid arthritis, Type 1 diabetes and multiple sclerosis while leveraging its expertise in LAG-3 biology to create differentiated treatments for patients and value for shareholders.

Average Trading Volume: 685,626

Technical Sentiment Signal: Buy

Current Market Cap: $388.1M

For detailed information about IMMP stock, go to TipRanks’ Stock Analysis page.